Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $130
GILDMarch 11, 2025
Read more →Gilead Sciences's Options: A Look at What the Big Money is Thinking
GILDMarch 10, 2025
Read more →P/E Ratio Insights for Gilead Sciences
GILDMarch 7, 2025
Read more →Here's How Much You Would Have Made Owning Gilead Sciences Stock In The Last 20 Years
GILDMarch 6, 2025
Read more →B of A Securities Maintains Buy on Gilead Sciences, Raises Price Target to $126
GILDMarch 5, 2025
Read more →Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $140
GILDMarch 5, 2025
Read more →Oppenheimer Maintains Outperform on Gilead Sciences, Raises Price Target to $132
GILDMarch 4, 2025
Read more →Gilead Sciences Unusual Options Activity
GILDFebruary 24, 2025
Read more →Gilead Sciences announces The EMA As Validated For Parallel Accelerated Review The Company's Marketing Authorization Application and EU-Medicines For All Application For Lenacapavir
GILDFebruary 24, 2025
Read more →Gilead Sciences Announces European Commission Approval Of Seladelpar For Rare Liver Disease Primary Biliary Cholangitis In European Economic Area
GILDFebruary 20, 2025
Read more →How Is The Market Feeling About Gilead Sciences?
GILDFebruary 19, 2025
Read more →16 Analysts Have This To Say About Gilead Sciences
GILDFebruary 18, 2025
Read more →Gilead Sciences Announces FDA Acceptance Of NDA For Lenacapavir For HIV Prevention Under Priority Review With PDUFA Date Set For June 19, 2025
GILDFebruary 18, 2025
Read more →Deutsche Bank Upgrades Gilead Sciences to Buy, Raises Price Target to $120
GILDFebruary 18, 2025
Read more →IDEAYA Biosciences Announced An Additional Clinical Study Collaboration And Supply Agreement With Gilead Sciences To Evaluate IDE397 In Combination With Gilead's Trodelvy (Sacituzumab Govitecan) For Methylthioadenosine Phosphorylase-Deletion Non-Small Cel
GILDFebruary 13, 2025
Read more →RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $90
GILDFebruary 12, 2025
Read more →Goldman Sachs Maintains Neutral on Gilead Sciences, Raises Price Target to $96
GILDFebruary 12, 2025
Read more →BMO Capital Maintains Outperform on Gilead Sciences, Raises Price Target to $115
GILDFebruary 12, 2025
Read more →Wells Fargo Maintains Overweight on Gilead Sciences, Raises Price Target to $120
GILDFebruary 12, 2025
Read more →Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $110
GILDFebruary 12, 2025
Read more →Morgan Stanley Maintains Overweight on Gilead Sciences, Raises Price Target to $123
GILDFebruary 12, 2025
Read more →Needham Reiterates Hold on Gilead Sciencesto Hold
GILDFebruary 12, 2025
Read more →Gilead Exec Says Co Expects To Do Something Like A Cymabay Acquisition Every Couple Of Years
GILDJanuary 13, 2025
Read more →Reported Saturday, Gilead And LEO Pharma Join Forces To Accelerate Oral STAT6 Development For Inflammation And Dermatology
GILDJanuary 13, 2025
Read more →Morgan Stanley Upgrades Gilead Sciences to Overweight, Raises Price Target to $113
GILDJanuary 10, 2025
Read more →Gilead Sciences Acquires 7.85M Xilio Therapeutics Shares At $1.04 Each, Raising Ownership To Over 10%, Along With 6.1M Pre-Funded Warrants Capped At 19.99% Ownership
GILDDecember 19, 2024
Read more →(GILD) - Analyzing Gilead Sciences's Short Interest
GILDDecember 19, 2024
Read more →26 Analysts Assess Gilead Sciences: What You Need To Know
GILDNovember 18, 2024
Read more →RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $84
GILDNovember 18, 2024
Read more →Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
GILDGilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety.
November 15, 2024
Read more →Gilead's Livdelzi (Seladelpar) Shows Sustained Efficacy And Long-Term Safety In Primary Biliary Cholangitis; 81% Achieve Biochemical Response By Month 30, 41% Reach ALP Normalization, And 27% Experience Near Resolution Of Itch In Phase 3 ASSURE Study
GILDNovember 15, 2024
Read more →Wolfe Research Initiates Coverage On Gilead Sciences with Outperform Rating, Announces Price Target of $110
GILDNovember 15, 2024
Read more →Citigroup Initiates Coverage On Gilead Sciences with Buy Rating, Announces Price Target of $125
GILDNovember 14, 2024
Read more →Reported Earlier, Gilead Sciences Prices $3.5B In Senior Notes, Including $1B Each For 2035 And 2054 Maturities
GILDNovember 14, 2024
Read more →Gilead Sciences Raises FY24 Adj EPS Outlook From $3.60 - $3.90 To $4.25 - $4.45, Est $3.81
GILDNovember 6, 2024
Read more →Gilead Sciences Raises FY24 Product sales Guidance From $27.10B - $27.50B To $27.80B - $28.10B
GILDNovember 6, 2024
Read more →Gilead Sciences Q3 2024 Adj EPS $2.02 Beats $1.55 Estimate, Sales $7.54B Beat $7.00B Estimate
GILDNovember 6, 2024
Read more →Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
GILDNovember 6, 2024
Read more →Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
GILDNovember 5, 2024
Read more →Gilead Sciences's Earnings: A Preview
GILDNovember 5, 2024
Read more →$100 Invested In This Stock 20 Years Ago Would Be Worth $800 Today
GILDMay 21, 2024
Read more →Gilead's Recently Acquired Liver Disease Candidate Shows Improvements In Disease Progression And Associated Itch
GILDGilead Sciences reports interim results from the ASSURE study of seladelpar in primary biliary cholangitis, showing significant improvements in cholestasis markers and pruritus.
May 20, 2024
Read more →Reported Saturday, Gilead Sciences Announced That The Investigational Seladelpar Shows Significant Improvements In Liver Disease Progression And Itch Reduction In Primary Biliary Cholangitis
GILDMay 20, 2024
Read more →Expert Ratings for Gilead Sciences
GILDAnalysts have provided the following ratings for Gilead Sciences (NASDAQ:GILD) within the last quarter:
September 13, 2022
Read more →Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $74
GILDSeptember 13, 2022
Read more →Is First Trust Large Cap Core AlphaDEX ETF (FEX) a Strong ETF Right Now?
GILDMaking its debut on 05/08/2007, smart beta exchange traded fund First Trust Large Cap Core AlphaDEX ETF (ETF:FEX) provides investors broad exposure to the Style Box - Large Cap Blend category of the market. What Are Smart Beta ETFs?
September 8, 2022
Read more →Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
GILDSeptember 8, 2022
Read more →Gilead, Dragonfly Therapeutics Report Strategic Research Collab To Develop Natural Killer Cell Engagers In Oncology, Inflammation; Gilead To Make $300M Upfront Payment, Dragonfly Will Be Eligible To Receive Opt-In Payments, Performance-Based Payments
GILDMay 2, 2022
Read more →Why These Analysts Are Bullish On Gilead's Q1 Earnings
GILDApril 29, 2022
Read more →$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much
GILDGilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 7.56% on an annualized basis producing an average annual return of 14.71%. Currently, Gilead Sciences has a market capitalization of $75.20 billion.
April 29, 2022
Read more →